BiomX Reports First Quarter 2022 Financial Results and Provides Business Update Upcoming KOL Webinar Scheduled for May 12 th to Discuss BX004 in Cystic Fibrosis IND Accepted to Conduct Clinical Testing of BX005 for the T

Reports First Quarter 2022 Financial Results and Provides Business Update

KOL Webinar Scheduled for May 12th to Discuss BX004 in Cystic Fibrosis

Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis

Runway Through Multiple Data Readouts

Will Host a Conference Call and Webcast Today at 8:00 am ET

Conn. and NESS ZIONA, Israel - May 11, 2022 - BiomX Inc. (NYSE American: PHGE) ("BiomX"

or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target

specific pathogenic bacteria, today reported financial results, and provided a business update for the first quarter ended March 31,

are continuing to make progress with our pipeline. In our cystic fibrosis ("CF") program, we are working actively to enroll

patients in our Phase 1b/2a trial and continue to expect initial data from the first part of the trial in the third quarter of 2022",

said Jonathan Solomon, Chief Executive Officer of BiomX. "We are also proud to have the support of the Cystic Fibrosis Foundation

for the CF program through its recent equity investment in BiomX. The Cystic Fibrosis Foundation continues to play an instrumental role

in bringing life-saving medicines to CF patients, and we appreciate their support for our program.

am also pleased to announce the clearance of an investigational new drug application ("IND") for BX005 for the treatment

of atopic dermatitis ("AD"). Supported by Maruho Co. Ltd., we are developing the topical phage cocktail, BX005, to address

disease pathology in the AD patient population by targeting Staphylococcus aureus, a bacteria thought to promote and exacerbate

inflammation in AD skin. As we look forward to providing updates from our CF and AD programs later this year, we continue to have sufficient

cash runway through multiple clinical readouts.

also looking forward to our upcoming KOL Webinar on May 12th, which will feature perspectives from leading CF experts on the

current treatment landscape and the unmet medical need for patients with chronic Pseudomonas aeruginosa respiratory infections."

CORPORATE HIGHLIGHTS

Bowel Disease ("IBD") and Colorectal Cancer Programs ("CRC")

Quarter 2022 Financial Results

Call and Webcast Information

management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the first

quarter ended March 31, 2022. To participate in the conference, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International).

A live and archived webcast of the call will be available on the Investors section of the Company's website at www.biomx.com.

is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria

in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis,

and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

information is available at www.biomx.com, the content of which does not form a part of this press release.

press release contains express or implied "forward-looking statements" within the meaning of the "safe harbor"

provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as:

"target," "believe," "expect," "will," "may," "anticipate," "estimate,"

"would," "positioned," "future," and other similar expressions that predict or indicate future events

or trends or that are not statements of historical matters. For example, when BiomX discusses future updates on its CF, AD and other

programs, its expectations regarding the timing and design of its pre-clinical and clinical trials and reporting the results thereof,

the potential safety, tolerability and potential treatment effect of its product candidates, the potential to achieve the applicable

clinical milestones required to receive an additional $2 million investment from CFF and additional tranches under its venture debt facility,

and its cash runway, capitalization and financial condition, BiomX is making forward-looking statements. Forward-looking statements are

neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's current beliefs,

expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks

and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes

may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking

statements and should review the risks and uncertainties described under the caption "Risk Factors" in BiomX's Annual

Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 30, 2022 and additional disclosures

BiomX makes in its other filings with the SEC, which are available on the SEC's website at www.sec.gov. Forward-looking statements

are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking

to update forward-looking statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(USD in thousands, except share and per share data)

CONSOLIDATED BALANCE SHEETS

in thousands, except share and per share data)

LifeSci Advisors, LLC

Corporate Project Manager